Parallel importer sees market for Novo Nordisk obesity drug in new countries
There may be opportunities in Novo Nordisk’s limited launches of popular obesity drug Wegovy (semaglutide) in Europe, Flemming Wagner, CEO of parallel importer Abacus Medicine, tells Finans.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app